This November

novo's q3 earnings confirmed the oral phase 3 launched in september

On November 4, Novo Nordisk reported Q3 2026 results and confirmed that AMAZE 9, the phase 3 trial of oral zenagamtide, was initiated in September. If you're asking what zenagamtide is — that's the question. It was amycretin until sometime this year. The molecule is the same compound with an INN name instead of a development code and a fresh phase 3 program now underway. [Novo Nordisk's Q3 2026 earnings](https://chemxplore.com/news/novo-nordisk-q3-2026-financial-report), reported through aggregators earlier this month, is where AMAZE 9's September start appeared in formal pipeline disclosure. Zenagamtide is a unimolecular peptide co-agonist of two receptors — GLP-1 and amylin — and it arrived in the clinical spotlight when its Phase 2 obesity data dropped early last year with up to 22% weight loss over 36 weeks, a number that topped Wegovy and Zepbound in published comparisons. The name is new. The phase 3 clock started in September. The results window opens in 2029 at the earliest.

The molecule

zenagamtide hits two separate satiety pathways with one molecule — glp-1 and amylin simultaneously

Most GLP-1 drugs in the market — semaglutide, tirzepatide — work through one or two incretin receptors. Zenagamtide adds a third biology: amylin. Amylin is a 37-amino-acid peptide co-secreted from the pancreas alongside insulin after meals. It signals through receptors in the brainstem to slow gastric emptying, suppress post-meal glucagon, and send satiety signals through a neural pathway separate from GLP-1. The two are biologically complementary: GLP-1 reduces appetite primarily through hypothalamic and gut signaling; amylin operates more through brainstem pathways. The design bet is that combining both in a single molecule generates additive satiety beyond either alone. This isn't speculative: pramlintide, an amylin analog the FDA approved in 2005 for use alongside insulin in type 1 and type 2 diabetes, confirmed the amylin pathway produces meaningful weight effects in real humans. Zenagamtide aims to put the whole package in one weekly injection — or eventually, one weekly pill. [PubMed's amycretin and zenagamtide literature](https://pubmed.ncbi.nlm.nih.gov/?term=amycretin) covers the mechanistic and early clinical work.

The public narrative

it's framed as the drug that beat ozempic in phase 2 — the frame isn't wrong, just early

The 22% weight-loss number from zenagamtide's Phase 2 obesity trial spread quickly. For context: Wegovy produces roughly 15–17% weight loss; tirzepatide hits roughly 20–22% in its best trials. A Phase 2 result of 22% at 36 weeks, with no apparent plateau at higher doses, generated real analyst and media attention. The comparison to approved drugs is mechanically correct — the Phase 2 numbers are what they are — but it misses a critical variable: phase 2 trials are powered to find signal, not to prove it in a large, diverse population over longer time horizons. The GLP-1 commentary circuit — which had been battered by CagriSema's failure to beat tirzepatide in REDEFINE 4 earlier this year — found in zenagamtide a fresh optimism narrative for Novo Nordisk's pipeline. What it doesn't say loudly enough is that zenagamtide is competing in a trial environment, not a pharmacy. The oral formulation data from the Phase 2 diabetes trial posted 10% weight loss versus 14.6% for injectable — the oral obesity pill story is real but runs on a dataset that hasn't closed the gap to the injectable version.

What the data says

phase 2 hit 22% in obesity and 14.6% in diabetes — the phase 3 primary endpoints arrive in 2029

Two Phase 2 datasets define the current evidence picture. The obesity Phase 2 enrolled adults with obesity without type 2 diabetes and found up to 22% weight loss over 36 weeks in the injectable arm — with what investigators described as a dose-response curve that had not plateaued, suggesting higher doses might deliver more. The diabetes Phase 2, presented at the American Diabetes Association meeting in June 2026, enrolled 262 adults with type 2 diabetes and showed 14.6% weight loss alongside a 1.71-percentage-point reduction in HbA1c from a 7.8% baseline — 89.1% of participants reached an A1c below 7% at the highest dose tested. [The June 2026 ADA press release from Novo Nordisk](https://www.biospace.com/press-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetes-presented-at-ada-2026) covers those results in full. Phase 3 is now underway: the AMAZE obesity program started in early 2026, and AMAZE 9 — the oral zenagamtide phase 3 — launched in September, per Novo's Q3 earnings. [ClinicalTrials.gov's zenagamtide registry](https://clinicaltrials.gov/search?term=zenagamtide) documents the full ongoing trial footprint, including a cardiovascular outcomes study. Primary completion for the AMAZE obesity program is estimated in 2029. The Phase 2 results are strong. They are not Phase 3 results.

Early human — PeptideFactCheck stance

the phase 2 is real signal — the phase 3 data window opens in 2029 and not before

Zenagamtide holds PeptideFactCheck's Early human evidence tier: interesting enough to watch, too early for broad certainty. That tier sits higher than most compounds in this space — there's a coherent mechanistic rationale built on decades of amylin pharmacology, two Phase 2 datasets with real efficacy signal, and a phase 3 program running in multiple indications. What Early human doesn't contain is a confirmed Phase 3 result, an approved indication, or a labeled drug. The comparison to approved GLP-1 therapies is not an equivalent read — phase 3 trials exist specifically to find what phase 2 misses. [The FDA's page on unapproved GLP-1 drugs](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) draws the operational line: zenagamtide is investigational, not dispensable, and phase 2 numbers don't change the designation. Novo Nordisk's public positioning treats CagriSema as the near-term approval story and zenagamtide as the next chapter after that. With AMAZE 9 initiated this past September and primary completion estimated in 2029, the tier is correct — this is the drug that is earning the attention right now. The receipt isn't there yet. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.